Reply: GDNF poses troubling questions for doctors, drug maker [3]

Annals of Neurology

Volumn 59, Issue 6, 2006, Pages 989-990

  Slevin, John T ^a,b,d   Gerhardt, Greg A ^a,b   Smith, Charles D ^a,b,c   Gash, Don M ^a,b,c   Young, A Byron ^a,b  

^a Department of Anatomy and Neurobiology ^*

^b Morris K Udall Parkinson's Disease Research Center of Excellence   (United States)

^c Magnetic Resonance Imaging and Spectroscopy Center   (United States)

^d UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR;

CENTRAL AMERICA; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; NEUROTOXICITY; NONHUMAN; NORTH AMERICA; PARKINSON DISEASE; PATIENT MONITORING; PHYSICIAN; PRIORITY JOURNAL;

CLINICAL TRIALS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; PARKINSON DISEASE; RESEARCH DESIGN;

EID: 33744819984     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20880     Document Type: Letter

References (7)

1. NerveCenter: GDNF poses troubling questions for doctors, drug maker. Ann Neurol 2006;59:A5-A6.
2. Slevin JT, Gerhardt GA, Smith CD, et al. Unilateral intraputamenal GDNF improves bilateral motor functions in patients with Parkinson disease. J Neurosurg 2005;102:216-222.
3. Penn RD, Dalvi A, Slevin JT, et al. GDNF in treatment of Parkinson's disease: response to editorial. Lancet Neurol 2006;5: 202-203.
4. Chebrolu H, Slevin JT, Gash DM, et al. MRI volumetric and intensity analysis of the cerebellum in Parkinson's disease patients infused with glial-derived neurotrophic factor (GDNF). Exp Neurol 2006;198:450-456.
5. Slevin JT, Gerhardt GA, Smith CD, et al. Research on Parkinson disease. J Neurosurg 2005;102:401.
6. Lang AE, Langston JW, Stoessl AJ, et al. GDNF in treatment of Parkinson's disease: response to editorial. Lancet Neurol 2006;5: 200-202.
7. Sherer TB, Fiske BK, Svendsen CN, et al. Crossroads in GDNF therapy for Parkinson's disease. Mov Disord 2006;21:136-141.